Search

Midazolam

[L45098] In May 2019, the nasal spray of midazolam was approved for the acute treatment of distinctive intermittent, stereotypic seizure episodes in patients 12 years of age and older. … [F2977] This drug was initially approved by the US FDA in 1985, and has been approved for various indications since.

Pindolol

Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. … [L32353] Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia.

Prednisolone hemisuccinate

Diflunisal

Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the arachidonic acid pathway. … Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs.

Volanesorsen

[L16621] Volanesorsen was granted a conditional approval by the European Medicines Agency.[L16621] … [L16621] This drug is not commonly prescribed as it is used as an adjunct to diet in patients at high risk for pancreatitis, who have had inadequate response to triglyceride lowering therapy.

Dichlorobenzyl alcohol

[L1113] On the other hand, dichlorobenzyl alcohol is categorized by the FDA in the inactive ingredient for approved drug products.[L2773] … [A33047] Dichlorobenzyl alcohol is considered as an active ingredient found in several marketed OTC products by Health Canada which has categorized this agent as an anatomical therapeutic chemical.

Acebutolol

A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. … The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action.

Linagliptin

Linagliptin was approved by the FDA on May 2, 2011[L9557]. … Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding[A37050

Arbutin

Arbutin was shown to be less cytotoxic to melanocytes in culture compared to [DB09526] [A32942]. … Arbutin is a competitive inhibitor of tyrosinase (E.C.1.14.18.1) in melanocytes [A27248], and the inhibition of melanin synthesis at non-toxic concentrations was observed _in vitro_.

Sulindac

While its full mechanism of action is not fully understood, sulindac is thought to primarily mediate its action by inhibiting prostaglandin synthesis by inhibiting COX-1 and COX-2. … Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes.